| 2026-08-12 | Press release | CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Executi |
| 2026-06-08 | Press release | CNS Pharmaceuticals CFO, Steve O’Loughlin, Highlights Company’s Recent $22.5M Financing in Virtual Investor |
| 2026-05-26 | Prospectus | HTML view of 424B3 filed on May 26, 2026 |
| 2026-05-26 | Prospectus | PDF view of 424B3 filed on May 26, 2026 |
| 2026-05-20 | Press release | CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company’s R |
| 2026-05-14 | Press release | CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress |
| 2026-05-04 | Press release | CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing |
| 2026-03-11 | Press release | CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline |
| 2026-03-02 | Press release | CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team |
| 2026-01-27 | Press release | CNS Pharmaceuticals Issues Letter to Shareholders |
| 2025-12-17 | Press release | CNS Pharmaceuticals Announces CEO Transition |
| 2025-11-17 | Press release | CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
| 2025-11-10 | Press release | CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO |
| 2025-09-03 | Press release | CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference |
| 2025-08-15 | Press release | CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
| 2025-07-22 | Press release | CNS Pharmaceuticals to Participate in the Virtual Investor “What’s Your Story” Summer Spotlight On-Dem |
| 2025-07-18 | Press release | CNS Pharmaceuticals Announces Reverse Stock Split |
| 2025-07-09 | Press release | CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment |
| 2025-06-24 | Press release | CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Pro |
| 2025-06-05 | Press release | CNS Pharmaceuticals’ Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech S |
| 2025-05-16 | Press release | CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update |
| 2025-05-13 | Press release | CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules |
| 2025-05-13 | Press release | CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 |
| 2025-03-25 | Press release | CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme |
| 2025-02-26 | Press release | CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing |
| 2025-02-20 | Press release | CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum |
| 2025-02-19 | Press release | CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference |
| 2025-02-19 | Press release | CNS Pharmaceuticals Announces Reverse Stock Split |
| 2025-02-18 | Press release | CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit |
| 2025-02-10 | Press release | CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference |
| 2024-12-05 | Press release | CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024 |
| 2024-11-25 | Press release | CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult |
| 2024-11-04 | Press release | CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment |
| 2024-10-10 | Press release | CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment |
| 2024-10-08 | Press release | CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC |
| 2024-09-23 | Press release | CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum |
| 2024-09-04 | Press release | CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference |
| 2024-08-27 | Press release | CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar |
| 2024-07-03 | Press release | CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement |
| 2024-06-26 | Press release | CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement |